Georg Sager
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Georg Sager has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Aina Westrheim Ravna
Experimental & Clinical Pharmacology, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø- The Arctic University of Norway, 9037 Tromsø, Norway
4 shared publications Natalia Smaglyukova
Experimental and Clinical Pharmacology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway
4 shared publicationsAnne Ørbo
Department of Medical Biology, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway
3 shared publications- Anne Ørbo
Department of Pathology, University Hospital of North-Norway, N-9038 Tromsø, Norway
3 shared publications - Erik Sveberg Dietrichs
Experimental and Clinical Pharmacology Research Group, Department of Medical Biology, UiT, The Arctic University of Norway, 9037 Tromsø, Norway; Department of Clinical Pharmacology, Division of Diagnostic Services, University Hospital of North Norway, 9038 Tromsø, Norway
3 shared publications Elisabet Nordmo
Regional Medicines Information and Pharmacovigilance Centre (RELIS) University Hospital of North Norway Tromsø Norway
2 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (2) , 611-618
Extracellular cGMP Levels Predict the Response of C4-1 Cervical Cancer Cells to Ionizing Radiation
Background/Aim: Urine cyclic guanosine monophosphate (cGMP) has been proposed as a prognostic biomarker for therapy response and the risk of relapse of cervical cancer after treatment with radiotherapy (RT). In the present study, an in vitro model with cervical cancer cells (C4-1) was established to determine whether changes in extracellular cGMP levels were predictive for effects of ionization radiation (IR). Materials and Methods: During exponential growth, C4-1 cells were exposed to IR with doses between 2 and 12 Gy. The cells were harvested at intervals between one and six days. Results: The effect of IR on cell growth and extracellular cGMP levels was dose- as well as time-dependent. Three and six days after IR, the cell fractions were reduced with identical sensitivity (ED50 of 1.9 and 1.8 Gy, respectively). The extracellular cGMP levels showed a fall from the first day to sixth day, both in control and after irradiation (2 and 4 Gy), but with somewhat higher levels after IR. However, the extracellular cGMP levels increased after 8 and 12 Gy exposure by 100% and 270%, respectively. When the data were presented as extracellular cGMP levels (% above control), a clear dose- and time-dependency were observed. Conclusion: From a translational perspective, extracellular cGMP levels may be used to monitor effects and be a potential tool for individualization of radiation therapy (RT).
- 30 January 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (2) , 611-618
Open AccessExtracellular cGMP Levels Predict the Response of C4-1 Cervical Cancer Cells to Ionizing Radiation
Background/Aim: Urine cyclic guanosine monophosphate (cGMP) has been proposed as a prognostic biomarker for therapy response and the risk of relapse of cervical cancer after treatment with radiotherapy (RT). In the present study, an in vitro model with cervical cancer cells (C4-1) was established to determine whether changes in extracellular cGMP levels were predictive for effects of ionization radiation (IR). Materials and Methods: During exponential growth, C4-1 cells were exposed to IR with doses between 2 and 12 Gy. The cells were harvested at intervals between one and six days. Results: The effect of IR on cell growth and extracellular cGMP levels was dose- as well as time-dependent. Three and six days after IR, the cell fractions were reduced with identical sensitivity (ED50 of 1.9 and 1.8 Gy, respectively). The extracellular cGMP levels showed a fall from the first day to sixth day, both in control and after irradiation (2 and 4 Gy), but with somewhat higher levels after IR. However, the extracellular cGMP levels increased after 8 and 12 Gy exposure by 100% and 270%, respectively. When the data were presented as extracellular cGMP levels (% above control), a clear dose- and time-dependency were observed. Conclusion: From a translational perspective, extracellular cGMP levels may be used to monitor effects and be a potential tool for individualization of radiation therapy (RT).
- Open Access
- 15 December 2022
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 30 (1) , 1-10
Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia
Background: Rewarming from hypothermia is associated with severe complications, one of which is hypothermia-induced cardiac dysfunction. This condition is characterized by decreased cardiac output accompanied by increased total peripheral resistance. This contributes to mortality rate approaching 40%. Despite this, no pharmacological interventions are recommended for these patients below 30 °C. Raising the intracellular levels of cAMP and/or cGMP, through PDE3- and PDE5-inhibitors respectively, have showed the ability to alleviate hypothermia-induced cardiac dysfunction in vivo. Drugs that raise levels of both cAMP and cGMP could therefore prove beneficial in patients suffering from hypothermia-induced cardiac dysfunction. Methods: The unselective PDE-inhibitor pentoxifylline was investigated to determine its ability to reach the intracellular space, inhibit PDE3 and PDE5 and inhibit cellular efflux of cAMP and cGMP at temperatures 37, 34, 30, 28, 24 and 20 °C. Recombinant human PDE-enzymes and human erythrocytes were used in the experiments. IC50-values were calculated at all temperatures to determine temperature-dependent changes. Results: At 20 °C, the IC50-value for PDE5-mediated enzymatic breakdown of cGMP was significantly increased compared to normothermia (IC50: 39.4 µM ± 10.9 µM vs. 7.70 µM ± 0.265 µM, p-value = 0.011). No other significant changes in IC50-values were observed during hypothermia. Conclusions: This study shows that pentoxifylline has minimal temperature-dependent pharmacodynamic changes, and that it can inhibit elimination of both cAMP and cGMP at low temperatures. This can potentially be effective treatment of hypothermia-induced cardiac dysfunction. Trial registration: Not applicable.
- 15 December 2022
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 30 (1) , 1-10
Open AccessPharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia
Background: Rewarming from hypothermia is associated with severe complications, one of which is hypothermia-induced cardiac dysfunction. This condition is characterized by decreased cardiac output accompanied by increased total peripheral resistance. This contributes to mortality rate approaching 40%. Despite this, no pharmacological interventions are recommended for these patients below 30 °C. Raising the intracellular levels of cAMP and/or cGMP, through PDE3- and PDE5-inhibitors respectively, have showed the ability to alleviate hypothermia-induced cardiac dysfunction in vivo. Drugs that raise levels of both cAMP and cGMP could therefore prove beneficial in patients suffering from hypothermia-induced cardiac dysfunction. Methods: The unselective PDE-inhibitor pentoxifylline was investigated to determine its ability to reach the intracellular space, inhibit PDE3 and PDE5 and inhibit cellular efflux of cAMP and cGMP at temperatures 37, 34, 30, 28, 24 and 20 °C. Recombinant human PDE-enzymes and human erythrocytes were used in the experiments. IC50-values were calculated at all temperatures to determine temperature-dependent changes. Results: At 20 °C, the IC50-value for PDE5-mediated enzymatic breakdown of cGMP was significantly increased compared to normothermia (IC50: 39.4 µM ± 10.9 µM vs. 7.70 µM ± 0.265 µM, p-value = 0.011). No other significant changes in IC50-values were observed during hypothermia. Conclusions: This study shows that pentoxifylline has minimal temperature-dependent pharmacodynamic changes, and that it can inhibit elimination of both cAMP and cGMP at low temperatures. This can potentially be effective treatment of hypothermia-induced cardiac dysfunction. Trial registration: Not applicable.
- Open Access
- 1 October 2021
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 213, 105951
Inhibition of ABCC5-mediated cGMP transport by progesterone, testosterone and their analogues
- 1 October 2021
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 213, 105951
Open AccessInhibition of ABCC5-mediated cGMP transport by progesterone, testosterone and their analogues
- Open Access
- 17 March 2021
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 128 (6) , 795-804
Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding
Clinical data on the transfer of triptans into human breast milk remain scarce. In a lactation study including 19 breastfeeding women with migraine, we examined the excretion of six different triptans into milk. Following intake of a single dose, each participant collected seven breast milk samples at predefined intervals up to 24 hours after dose. Triptan concentrations in milk were measured using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). Infant drug exposure was estimated by calculating the relative infant dose (RID). Twenty‐two breast milk sample sets were obtained for sumatriptan (n = 8), rizatriptan (n = 5), zolmitriptan (n = 4), eletriptan (n = 3), almotriptan (n = 1) and naratriptan (n = 1). Based on the average concentration in milk throughout the day, estimated mean RIDs (with range in parenthesis) were as follows: eletriptan 0.6% (0.3%‐0.8%), sumatriptan 0.7% (0.2%‐1.8%), rizatriptan 0.9% (0.3%‐1.4%), almotriptan 1.8% (‐), zolmitriptan 2.1% (0.7%‐5.3%) and naratriptan 5.0% (‐). Infant drug exposure through breastfeeding appears to be low and indicates that use of the triptans in this study is compatible with breastfeeding. Naratriptan may not be first choice in breastfeeding mothers initiating triptans during the neonatal period.
- 17 March 2021
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 128 (6) , 795-804
Open AccessTransfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding
Clinical data on the transfer of triptans into human breast milk remain scarce. In a lactation study including 19 breastfeeding women with migraine, we examined the excretion of six different triptans into milk. Following intake of a single dose, each participant collected seven breast milk samples at predefined intervals up to 24 hours after dose. Triptan concentrations in milk were measured using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). Infant drug exposure was estimated by calculating the relative infant dose (RID). Twenty‐two breast milk sample sets were obtained for sumatriptan (n = 8), rizatriptan (n = 5), zolmitriptan (n = 4), eletriptan (n = 3), almotriptan (n = 1) and naratriptan (n = 1). Based on the average concentration in milk throughout the day, estimated mean RIDs (with range in parenthesis) were as follows: eletriptan 0.6% (0.3%‐0.8%), sumatriptan 0.7% (0.2%‐1.8%), rizatriptan 0.9% (0.3%‐1.4%), almotriptan 1.8% (‐), zolmitriptan 2.1% (0.7%‐5.3%) and naratriptan 5.0% (‐). Infant drug exposure through breastfeeding appears to be low and indicates that use of the triptans in this study is compatible with breastfeeding. Naratriptan may not be first choice in breastfeeding mothers initiating triptans during the neonatal period.
- Open Access
- 1 September 2020
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 202, 105701
Expression of nuclear progesterone receptors (nPRs), membrane progesterone receptors (mPRs) and progesterone receptor membrane components (PGRMCs) in the human endometrium after 6 months levonorgestrel low dose intrauterine therapy
- 1 September 2020
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 202, 105701
Open AccessExpression of nuclear progesterone receptors (nPRs), membrane progesterone receptors (mPRs) and progesterone receptor membrane components (PGRMCs) in the human endometrium after 6 months levonorgestrel low dose intrauterine therapy
- Open Access
- 1 August 2020
- Published by Elsevier in Data in Brief
- Vol. 31, 105923
Data on RT-qPCR assay of nuclear progesterone receptors (nPR), membrane progesterone receptors (mPR) and progesterone receptor membrane components (PGRMC) from human uterine endometrial tissue and cancer cells of the Uterine Cervix
- 1 August 2020
- Published by Elsevier in Data in Brief
- Vol. 31, 105923
Open AccessData on RT-qPCR assay of nuclear progesterone receptors (nPR), membrane progesterone receptors (mPR) and progesterone receptor membrane components (PGRMC) from human uterine endometrial tissue and cancer cells of the Uterine Cervix
- Open Access
- 1 September 2019
- Published by Elsevier in Reproductive Toxicology
- Vol. 88, 141
#25 Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding
- 1 September 2019
- Published by Elsevier in Reproductive Toxicology
- Vol. 88, 141
Open Access#25 Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding
- Open Access
- 27 February 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (8) , 5972-5980
The role of OAT2 (SLC22A7) in the cyclic nucleotide biokinetics of human erythrocytes
The present study was conducted to characterise the transporter(s) responsible for the uptake of cyclic nucleotides to human erythrocytes. Western blotting showed that hRBC expressed OAT2 (SLC22A7), but detection of OAT1 (SLC22A6), or OAT3 (SLC22A8) was not possible. Intact hRBC were employed to clarify the simultaneous cyclic nucleotide egression and uptake. Both these opposing processes were studied. The Km‐values for high affinity efflux was 3.5 ± 0.1 and 39.4 ± 5.7 μM for cGMP and cAMP, respectively. The respective values for low affinity efflux were 212 ± 11 and 339 ± 42 μM. The uptake was characterised with apparently low affinity and similar Km‐values for cGMP (2.2 mM) and cAMP (0.89 mM). Using an iterative approach in order to balance uptake with efflux, the predicted real Km‐values for uptake were 100–200 μM for cGMP and 50–150 μM for cAMP. The established OAT2‐substrate indomethacin showed a competitive interaction with cyclic nucleotide uptake. Creatinine, also an OAT2 substrate, showed saturable uptake with a Km of 854 ± 98 μM. Unexpectedly, co‐incubation with cyclic nucleotides showed an uncompetitive inhibition. The observed Km‐values were 399 ± 44 and 259 ± 30 μM for creatinine, in the presence of cGMP and cAMP, respectively. Finally, the OAT1‐substrate para‐aminohippurate (PAH) showed some uptake (Km‐value of 2.0 ± 0.4 mM) but did not interact with cyclic nucleotide or indomethacin transport.
- 27 February 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (8) , 5972-5980
Open AccessThe role of OAT2 (SLC22A7) in the cyclic nucleotide biokinetics of human erythrocytes
The present study was conducted to characterise the transporter(s) responsible for the uptake of cyclic nucleotides to human erythrocytes. Western blotting showed that hRBC expressed OAT2 (SLC22A7), but detection of OAT1 (SLC22A6), or OAT3 (SLC22A8) was not possible. Intact hRBC were employed to clarify the simultaneous cyclic nucleotide egression and uptake. Both these opposing processes were studied. The Km‐values for high affinity efflux was 3.5 ± 0.1 and 39.4 ± 5.7 μM for cGMP and cAMP, respectively. The respective values for low affinity efflux were 212 ± 11 and 339 ± 42 μM. The uptake was characterised with apparently low affinity and similar Km‐values for cGMP (2.2 mM) and cAMP (0.89 mM). Using an iterative approach in order to balance uptake with efflux, the predicted real Km‐values for uptake were 100–200 μM for cGMP and 50–150 μM for cAMP. The established OAT2‐substrate indomethacin showed a competitive interaction with cyclic nucleotide uptake. Creatinine, also an OAT2 substrate, showed saturable uptake with a Km of 854 ± 98 μM. Unexpectedly, co‐incubation with cyclic nucleotides showed an uncompetitive inhibition. The observed Km‐values were 399 ± 44 and 259 ± 30 μM for creatinine, in the presence of cGMP and cAMP, respectively. Finally, the OAT1‐substrate para‐aminohippurate (PAH) showed some uptake (Km‐value of 2.0 ± 0.4 mM) but did not interact with cyclic nucleotide or indomethacin transport.
- Open Access
- 17 February 2017
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 69 (6) , 675-683
Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux
Objectives: To determine the ability of 11 sildenafil analogues to discriminate between cyclic nucleotide phosphodiesterases (cnPDEs) and to characterise their inhibitory potencies (Ki values) of PDE5A1-dependent guanosine cyclic monophosphate (cGMP) hydrolysis. Methods: Sildenafil analogues were identified by virtual ligand screening (VLS) and screened for their ability to inhibit adenosine cyclic monophosphate (cAMP) hydrolysis by PDE1A1, PDE1B1, PDE2A1, PDE3A, PDE10A1 and PDE10A2, and cGMP hydrolysis by PDE5A, PDE6C, PDE9A2 for a low (1 nm) and high concentration (10 μm). Complete IC50 plots for all analogues were performed for PDE5A-dependent cGMP hydrolysis. Docking studies and scoring were made using the ICM molecular modelling software. Key findings: The analogues in a low concentration showed no or low inhibition of PDE1A1, PDE1B1, PDE2A1, PDE3A, PDE10A1 and PDE10A2. In contrast, PDE5A and PDE6C were markedly inhibited to a similar extent by the analogues in a low concentration, whereas PDE9A2 was much less inhibited. The analogues showed a relative narrow range of Ki values for PDE5A inhibition (1.2–14 nm). The sildenafil molecule was docked in the structure of PDE5A1 co-crystallised with sildenafil. All the analogues had similar binding poses as sildenafil. Conclusions: Sildenafil analogues that inhibit cellular cGMP efflux are potent inhibitors of PDE5A and PDE6C.
- 17 February 2017
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 69 (6) , 675-683
Open AccessInhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux
Objectives: To determine the ability of 11 sildenafil analogues to discriminate between cyclic nucleotide phosphodiesterases (cnPDEs) and to characterise their inhibitory potencies (Ki values) of PDE5A1-dependent guanosine cyclic monophosphate (cGMP) hydrolysis. Methods: Sildenafil analogues were identified by virtual ligand screening (VLS) and screened for their ability to inhibit adenosine cyclic monophosphate (cAMP) hydrolysis by PDE1A1, PDE1B1, PDE2A1, PDE3A, PDE10A1 and PDE10A2, and cGMP hydrolysis by PDE5A, PDE6C, PDE9A2 for a low (1 nm) and high concentration (10 μm). Complete IC50 plots for all analogues were performed for PDE5A-dependent cGMP hydrolysis. Docking studies and scoring were made using the ICM molecular modelling software. Key findings: The analogues in a low concentration showed no or low inhibition of PDE1A1, PDE1B1, PDE2A1, PDE3A, PDE10A1 and PDE10A2. In contrast, PDE5A and PDE6C were markedly inhibited to a similar extent by the analogues in a low concentration, whereas PDE9A2 was much less inhibited. The analogues showed a relative narrow range of Ki values for PDE5A inhibition (1.2–14 nm). The sildenafil molecule was docked in the structure of PDE5A1 co-crystallised with sildenafil. All the analogues had similar binding poses as sildenafil. Conclusions: Sildenafil analogues that inhibit cellular cGMP efflux are potent inhibitors of PDE5A and PDE6C.
- Open Access
- 5 December 2016
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 24 (1) , 143
Altered pharmacological effects of adrenergic agonists during hypothermia
Rewarming from accidental hypothermia is often complicated by hypothermia-induced cardiac dysfunction, calling for immediate pharmacologic intervention. Studies show that although cardiac pharmacologic support is applied when rewarming these patients, a lack of updated treatment recommendations exist. Mainly due to lack of clinical and experimental data, neither of the international guidelines includes information about pharmacologic cardiac support at temperatures below 30 °C. However, core temperature of accidental hypothermia patients is often reduced below 30 °C. Few human studies exploring effects of adrenergic drugs during hypothermia have been published, and therefore prevailing information is collected from pre-clinical studies. The most prominent finding in these studies is an apparent depressive effect of adrenaline on cardiac function when used in doses which elevate cardiac output during normothermia. Also noradrenaline and isoprenaline largely lacked positive cardiac effects during hypothermia, while dopamine is a more promising drug for supporting cardiac function during rewarming. Data and information from these studies are in support of the prevailing notion; not to use adrenergic drugs at core temperatures below 30 °C.
- 5 December 2016
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 24 (1) , 143
Open AccessAltered pharmacological effects of adrenergic agonists during hypothermia
Rewarming from accidental hypothermia is often complicated by hypothermia-induced cardiac dysfunction, calling for immediate pharmacologic intervention. Studies show that although cardiac pharmacologic support is applied when rewarming these patients, a lack of updated treatment recommendations exist. Mainly due to lack of clinical and experimental data, neither of the international guidelines includes information about pharmacologic cardiac support at temperatures below 30 °C. However, core temperature of accidental hypothermia patients is often reduced below 30 °C. Few human studies exploring effects of adrenergic drugs during hypothermia have been published, and therefore prevailing information is collected from pre-clinical studies. The most prominent finding in these studies is an apparent depressive effect of adrenaline on cardiac function when used in doses which elevate cardiac output during normothermia. Also noradrenaline and isoprenaline largely lacked positive cardiac effects during hypothermia, while dopamine is a more promising drug for supporting cardiac function during rewarming. Data and information from these studies are in support of the prevailing notion; not to use adrenergic drugs at core temperatures below 30 °C.